MUSK and myasthenia gravis: Efgartigimod has been tested in the phase III ADAPT trial including 129 AChR-MG and 38 AChR-Ab negative MG patients, among which 6 patients were MuSK-Ab positive and 3 patients received efgartigimod (160).